文档介绍：A Global View
Ross Underwood
MSD Taiwan
History of Merck & Co.
Began as branch of E-Merck, a German fine pany
1891 – US subsidiary (Merck & Co.)
1897 - $1M in sales (USA)
1917 – Due to WWI, US government seizes stock held by E-Merck
1918 – Merck & Co. purchases shares from government. Fully owned.
Headquarters, New York 1897
History of Merck & Co.
1936 – Synthesis of B1 (thiamine)
1948 – Synthesis of B12 (anemia)
1940 – Streptomycin (tuberculosis)
1950 – Non US sales reach $100M
1951 – Cortisone (steroid)
1958 – Indomethacin –(arthritis)
1960 - Chlorothizaide (heart failure)
Salesman’s sample kit – 1920’s
History of Merck & Co.
1953 – Merger with Sharpe & Dohme, a customer of Merck & Co.
1983 - Purchases 50% share of Nippon Merck-Banyu in Japan
1986 – Enalapril – 1st $1B product
1987 – Lovastatin – 1st cholesterol drug
1990 – Global sales reach $7 billion
Sharp & Dohme product line
History of Merck & Co.
1992 – Merck establishes MSD Taiwan subsidiary
Merck & Co. – At A Glance
Global employees: 64,000
Annual sales: USD 21B
R&D Spend: USD *
Research centers: 11
Manufacturing Plants: 32
Worldwide markets: 150
* % of the world’s R&D spend
Top panies - Global
Taking risk – new drug development
1 in 10,000 es a drug
NT$ 28,000,000,000 cost
10-15 years to register
After 10 years – 50% failure petition – within 2 years
Fewer new drugs
18 in 2002
30 in 1998
100 new drugs since 1963
R&D spend in 2002: NT$ 98B
16% above 2001
NT$ 612B over last 10 years
9,000 R&D employees
11 R&D centers in 7 countries
Intellectual property protection (IPR) is critical
Environment
Response
New Drug Development
(Total Cost ~ NT$ 28B)
0
15
Years
2
1
2-5
5
10 to 20
Substances
5,000 - 10,000
Substances
Basic
Research
Synthesis
Examination &
Screening
Preclinical Tests
(Animal)
Clinical Tests
(Human)
Product Surveillance
Preclinical Tests
(Animal)
Phase III
Phase II
Phase I
Phase IV
Development
Registration
Introduction
Source: P